the joint initiative seeks to empower asian small and medium-sized enterprises in the agro-food sector by strengthening their market research capacities, fostering peer exchange among exporters, and connecting them with canadian buyers.

the objective of the call for proposals is to select researchers or consultants who will prepare market-entry studies for cambodia, laos, and myanmar. the studies will identify exportable products and producers in agro-food sectors and rank them in order of export suitability for the canadian market.

researchers will also assess the potential of local agro-food sectors to generate positive socio-economic development, including quality employment, gender equality, and sustainable environmental practices. the reports will also provide specific market-entry strategies and recommendations for local producers.

an estimated 30 days of work is planned in each country over a period of three months. the final reports will be expected early october 2017. applicants may submit proposals for one or more countries involved in this initiative.

the deadline for applications is june 30, 2017, by midnight est.

applicants may submit proposals for one or more countries involved in this initiative. preference will be given to a team of two researchers: one based in north america with a knowledge of the canadian market and trade opportunities in the agro-food sector and one based in the target country/region with experience in international trade and understanding of export’s barriers and enablers for local agro-food producers.

the fy17 defense appropriations act provides $15 million (m) to the department of defense nfrp to support innovative, high-impact nf research.  applications to the fy17 nfrp are being solicited by the u.s. army medical research acquisition activity (usamraa). the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp).

fy17 nfrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.

areas of emphasis:  the nfrp encourages applications that specifically address the critical needs of the nf community in one or more of the fy17 areas of emphasis.  not all areas of emphasis are applicable to each award mechanism offered by the fy17 nfrp.  if the proposed research project does not address one of the fy17 areas of emphasis, justification that the proposed research project addresses an important problem related to nf research and/or patient care should be provided.

health services research

·         evidence-based clinical care pathways

·         innovative healthcare delivery systems

·         utilization of technology and informatics

heterogeneity of neurofibromas and other nf-related tumors

nontumor manifestations

·         sleep, pain, hypotonia, communication, etc., including quality of life measures, self-reported and otherwise

novel disease and treatment response markers using genomics, epigenetics, systems biology, metabolomics, or similar approaches

·         transition from benign to malignant

nutritional, environmental, and other modifiers of nf

post-adolescent manifestations

preclinical efficacy studies

target identification, drug discovery, targeted and immunotherapies

other

clinical trial award – letter of intent due jul7 26, 2017

·         independent investigators at or above the level of assistant professor (or equivalent)

·         fund phase 0, i, or ii clinical trials relevant to nf and/or schwannomatosis; combinations of phases are permitted.

·         funding must support a clinical trial and may not be used for preclinical studies.

·         scientific rationale and preliminary data required for phase i, ii clinical trial applications.

·         maximum funding of $900,000 for direct costs (plus indirect costs)

·         maximum period of performance is 4 years

·          

exploration – hypothesis development award – letter of intent due july 26, 2017

·         all academic levels (or equivalent)

·         fund the initial exploration of innovative, high-risk, high-gain and potentially. groundbreaking concepts in nf research

·         projects involving human subjects or human biological substances must be exempt under 32 cfr 219.101(b) or eligible for expedited review under 32 cfr 219.110 or 21 cfr 56.110.

·         preliminary and/or published data is encouraged but not required.

·         clinical trials not allowed

·         maximum funding of $100,000 for direct costs (plus indirect costs)

·         maximum period of performance is 2 years

investigator-initiated research award – letter of intent due july 26, 2017

·         independent investigators at or above the level of assistant professor (or equivalent)

• fund highly rigorous, high-impact research projects that have the potential to make an important contribution to nf research and/or patient care.

• optional feature:  applications that include a qualified collaborator who meets criteria identified in the announcement may apply for a higher level of funding.

·         preliminary and/or published data required.

·         clinical trials not allowed.

·         maximum funding of $525,000 for direct costs (plus indirect costs)

·         maximum funding of $575,000 for direct costs (plus indirect costs) for applications including an optional qualified collaborator

·         maximum period of performance is 3 years

new investigator award – letter of intent due july 26, 2017

·         independent investigators at or below the level of assistant professor (or equivalent) or an established investigator at or above the level of assistant professor seeking to transition into a career in nf research

·         support the continued development of promising independent investigators and/or the transition of established investigators into a career in the field of nf research

·         experience in nf research is allowed, but not required

·         preliminary and/or published data required

·         clinical trials not allowed

·         maximum funding of $450,000 for direct costs (plus indirect costs)

·         maximum period of performance is 3 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline. all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

applications must be submitted through the federal government’s single-entry portal, grants.gov.  for email notification when program announcements are released go to the cdmrp website (http://cdmrp.army.mil) and select subscribe to funding opportunities & program communications.  for more information about the nfrp or other cdmrp-administered programs, please visit the cdmrp website (http://cdmrp.army.mil).

point of contact:

cdmrp help desk

301-682-5507

help@ebrap.org

fy17 scirp program announcements and general application instructions for the following award mechanisms are posted on grants.gov.

as directed by the office of the assistant secretary of defense for health affairs, the defense health agency (dha), j9 research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp).

clinical research development award – preproposal due august 8, 2017

independent investigators at all academic levels (or equivalent)

·         preproposal is required; application submission is by invitation only.

·         fund research that will establish the necessary collaborations and develop the necessary research resources that will serve as a foundation for investigator-initiated clinical research.

·         clinical trials not allowed.

·         maximum funding of $100,000 for direct costs (plus indirect costs)

·         maximum period of performance is 1 year

clinical trial award – preproposal due august 8, 2017

independent investigators at all academic levels (or equivalent)

·         preproposal is required; application submission is by invitation only.

·         fund phase 0, i, or ii clinical trials with the potential to have a major impact on treatment or management of spinal cord injury (sci) and its consequences.

·         preclinical data required for all clinical trial applications.

·         maximum funding of $2,000,000 for direct costs (plus indirect costs)

·         maximum period of performance is 4 years

investigator-initiated research award – preproposal due august 8, 2017

independent investigators at all academic levels (or equivalent)

·         preproposal is required; application submission is by invitation only.

·         fund sci-related research that has the potential to make an important contribution to sci research and/or patient care.

·         preliminary data required.

·         clinical trials not allowed.

·         maximum funding of $500,000 for direct costs (plus indirect costs)

·         maximum period of performance is 3 years

qualitative research award – preapplication due august 8, 2017

independent investigators at all academic levels (or equivalent)

·    preproposal is required; application submission is by invitation only.

·    fund qualitative research on military service members and veterans in the years following sci.

·    qualitative research is defined as a form of social inquiry that focuses on understanding the way that people interpret and make sense of their experiences and the world in which they live (i.e., seek to understand the human experience).

·    preliminary data encouraged, but not required.

·   clinical trials not allowed.

·      maximum funding of $500,000 for direct costs (plus indirect costs)

·       maximum period of performance is 3 years

translational research award – preproposal due august 8, 2017

independent investigators at all academic levels (or equivalent)

·    preproposal is required; application submission is by invitation only.

·    fund studies that accelerate the movement of promising ideas in sci research into clinical applications.

·    optional feature:  applications that include a qualified collaborator that meets criteria identified in the announcement may apply for a higher level of funding.

·    preliminary data required.

·       limited clinical testing of a novel intervention or device is permissible.

·      maximum funding of $1,250,000 for direct costs (plus indirect costs)

·      maximum funding of $1,500,000 for direct costs (plus indirect costs) for applications including an optional qualified collaborator

·       maximum period of performance is 3 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline. all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

applications must be submitted through the federal government’s single-entry portal, grants.gov.  .  for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the scirp or other cdmrp-administered programs, please visit the cdmrp website (http://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

call for ontario-israel r&d projects
ontario-israel collaboration program (oicp)

summary proposal deadline: june 15, 2017
full proposal deadline: july 24, 2017

this ontario-israel call invites applicants – at least one industrial partner from ontario and at least one industrial partner from israel – to propose shared research projects for the development of innovative products or processes. the maximum duration of a project is 24 months. special consideration will be given to projects in the following three areas:

clean technologies
life sciences and medical devices
cyber security and other information and communication technologies

funding

successful ontario applicants are eligible to receive up to $300,000 cad or up to 50% of the r&d costs of technology-based products and processes (whichever is less) from the government of ontario through ciirdf to fund the ontario portion of each project.
successful israeli applicants are eligible to receive funding from the israel innovation authority, to support the israel portion of the project under the oicp. the level of funding will be determined by the r&d review committee of the innovation authority.

joint ciirdf-nserc funding opportunity for ontario participants
ciirdf and the natural sciences and engineering research council of canada (nserc) joined forces and signed an agreement aligning their respective collaborative r&d programs. ontario-based university and college researchers participating in the ciirdf projects may apply for an nserc collaborative r&d (crd) and applied r&d (ard) grant as part of the funding application to ciirdf. for more information on this funding opportunity, please contact tomoko nishino at tomoko@ciirdf.ca.

how to apply

ontario and israel applicants

the first step of the application process is to complete the proposal summary and submit it to ciirdf for pre-proposal evaluation.
if the proposed project is eligible, ciirdf will invite the project team to submit the full application.
for guidelines for project submission, reporting and agreements, please download the file_ontario_israel_information_handbook_2017en and file_ciirdf_proposal_budget_template.

israel applicants: to ensure eligibility, the lead israeli partner of each project must contact the innovation authority, following the guidelines published online: http://www.economy.gov.il/rnd/programs/pages/mop_fund.aspx
*please note: this information is available in hebrew only.

review and evaluation

external panels in ontario and israel will independently review applications. based on these evaluations, ciirdf in consultation with the government of ontario and the israel innovation authority will make joint decisions on successful projects to receive funding.

objectives

research tools and instruments (rti) grants foster and enhance the discovery, innovation and training capability of university researchers in the natural sciences and engineering by supporting the purchase of research equipment.

description

rti grants are one-year awards of up to $150,000 that assist in the purchase or fabrication of research equipment with a net cost between $7,001 and $250,000 (excluding taxes, customs and importation fees, transportation and shipping charges, assembly and installation costs). the research community is also encouraged to explore other avenues for funding research tools and instruments, including nserc's other programs that include the purchase of equipment as eligible expenses, such as discovery grants.

the agricultural adaptation council (aac) is accepting applications, until july 13, 2017, for projects that will test and assess the feasibility of renewable energy technologies under the greenhouse renewable energy technologies (gret) r&d initiative.

the gret r&d initiative is a $1 million initiative to support innovative research and development projects that will benefit commercial greenhouse businesses in ontario, including vegetables, floriculture, fruit and culinary herbs.

eligible applicants include any organization, company, or research institution involved in a project benefiting the greenhouse sector in ontario. funding assistance will be provided to:

-       undertake pilot-scale demonstrations, or,

-       complete feasibility studies to investigate renewable energy technologies.

funding for the gret r&d initiative is provided by the government of ontario. as part of the climate change action plan, ontario is committed to expand the use of innovative technologies and practices in its food and beverage-processing sector, and to support the transition to low-carbon, indoor agricultural facilities, such as greenhouses.

the aac is based in guelph, ontario, canada, and is a leader in program delivery. the aac is a not-for-profit organization that is made up of over 60 ontario agricultural, agri-food and rural organizations.

learn more

·         gret r&d initiative call for proposals

·         gret r&d initiative application. work plan and budget

·         gret r&d initiative faqs

for more information contact:

laura feil

programs lead & communications manager

agricultural adaptation council
email: lfeil@adaptcouncil.org

tel: (519) 822-7554 ext. 629

fy17 dmdrp program announcements and general application instructions for the following award mechanisms are posted on grants.gov.

as directed by the office of the assistant secretary of defense for health affairs, the defense health agency (dha) j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp).

all applications for the fy17 dmdrp funding opportunities are required to address at least one of the following focus areas:

• cardiac studies, including identifying mechanisms of pathology and therapeutic interventions
• clinical studies, novel interventions, and drug and biologic delivery technologies designed to improve clinical care and quality of life in areas such as:

○        cognitive function

○        endocrinology

○        gastrointestinal issues

○        immunology

○        orthopaedics

○        psychosocial issues

○        pulmonology (including sleep-focused studies)

○        skeletal muscle

• assessment of clinical trial tools and outcome measures, such as:

○        discovery and qualification of pharmacodynamic, prognostic, and predictive biomarkers

○        novel clinical outcome assessments

○        patient-centered outcomes, e.g., quality of life, activities of daily living

○        potential surrogate markers

extension or expansion of existing preclinical translational data in support of a specific therapeutic development path (including drug exposure, independent replication, and comparative studies)

career development award – letter of intent due october 4, 2017

principal investigator:  must be research (ph.d.) or physician (m.d.) scientists at an early stage of their research careers with a minimum of 2 years post terminal degree (excluding medical residency or family medical leave), working to become independent investigators who exhibit a strong desire to pursue careers in duchenne research.
mentor:  must hold a position at or above the level of an associate professor (or equivalent).

·         supports early-career investigators to conduct impactful research under the mentorship of an experienced muscular dystrophy researcher.

·         clinical trials are not allowed.

• preliminary data are required.

·         maximum funding of $275,000 for direct costs (plus indirect costs).

• maximum period of performance is 2 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

applications must be submitted through the federal government’s single-entry portal, grants.gov.   for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the dmdrp or other cdmrp-administered programs, please visit the cdmrp website (http://cdmrp.army.mil).

point of contact:

help desk

301-682-5507

help@ebrap.org